IBI3003 for multiple myeloma that has returned or not responded
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an investigational drug called IBI3003 in people with multiple myeloma that has come back or hasn't responded to previous treatments. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older (up to 75 for the first part of the study).
- You have been diagnosed with multiple myeloma and your cancer has come back or is not responding to treatment.
- You are able to take care of yourself (fully active or only limited in strenuous activity).
- Your doctor expects you to live at least 3 more months.
- You do not have active cancer that has spread to your brain or spinal cord.
- You do not have other types of plasma cell disorders or certain other cancers within the past 3 years (except some minor skin, bladder, prostate, or cervical cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IBI3003 for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if IBI3003 is safe and effective.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
This study tests CM336, a new type of immunotherapy drug, for patients with multiple myeloma (a blood cancer) that has come back or progressed after their first treatment. The trial aims to see if this drug can help control the disease in patients at high risk of relapse.
This trial tests an experimental drug called JNJ-79635322 for people with multiple myeloma that has come back or hasn't responded to at least three previous treatments, including a PI, an IMiD, and a CD38-targeted antibody. The goal is to see if this new drug can help control the disease.
This trial tests a new drug, BMS-986453, for people newly diagnosed with multiple myeloma. It aims to see if the drug is safe and works well for those who cannot or choose not to have a stem cell transplant.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.